Research & Development
Parnell Pharmaceuticals develops Nomovid Antiviral Nasal Spray against Sars-CoV-2 and seeks FDA approval
24 September 2020 -

Pharmaceutical company Parnell Pharmaceuticals reported on Wednesday that it has developed the first antiviral Nomovid Nasal Spray in the US that is easy-to-use, low-cost and can be quickly made available over-the-counter for consumers for use against Sars-CoV-2.

The company added Nomovid is based upon a substance licensed from New Mexico Tech University to treat drug-resistant bacteria and fungi including MRSA and Candida auris.

However, the company is now filing with FDA for the COVID-19 indication as Nomovid Antiviral Nasal Spray showed very positive results against COVID-19. Since the nose is the main route of entry into the body of Sars-CoV-2, it has prepared it in a nasal spray, added its CEO.

In conjunction, the company has filed a White Paper to the US government programme Operation Warp Speed, seeking funding and an Emergency Use Authorization, which will allow the product to be manufactured and distributed during the Phase III Clinical Trials.



Related Headlines